What Facts Should You Know About Oncternal Therapeutics (ONCT)?

By Kim Brooks • Monday, September 18 15:56 • Permanent Link

Small-cap health care company Oncternal Therapeutics has moved -3.1% this afternoon, reaching $0.34 per share. In contrast, the average analyst target price for the stock is $1.9.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company is based in the United States.

Make Sure to Consider the Following Before Buying Oncternal Therapeutics:

Oncternal Therapeutics has moved -61.0% over the last year.
ONCT has a forward P/E ratio of -0.8 based on its EPS guidance of -0.43.
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 36.5%.
Its Price to Book (P/B) ratio is 0.44

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.